What's Going On With Viking Therapeutics Stock On Wednesday?
What's Going On With Viking Therapeutics Stock On Wednesday?
Hansoh Pharma may co-promote or solely commercialize HS-10535 in China. Merck will record a pre-tax charge of $112 million, or $0.04 per share, to be included in GAAP and non-GAAP results in the fourth quarter of 2024.On Wednesday, Merck & Co Inc (NYSE:MRK) and Hansoh Pharma, a Chinese biopharmaceutical company, entered into an exclusive global license agreement for HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist.
週三，默沙東（紐交所：MRK）與中國生物製藥公司翰森製藥簽署了一項關於HS-10535的全球獨家許可協議，該藥物是一種研究中的臨床前口服小分子GLP-1受體激動劑。
Under the agreement, Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture, and commercialize HS-10535. Hansoh Pharma will receive an upfront payment of $112 million and is eligible to receive up to $1.9 billion in milestone payments associated with the candidate's development, regulatory approval, and commercialization, as well as royalties on sales.
根據協議，翰森製藥已授予默沙東獨家全球許可，以開發、製造和商業化HS-10535。翰森製藥將獲得11200萬美金的預付款，並有資格獲得高達19億美金的與候選藥物開發、監管批准和商業化相關的里程碑付款，以及銷售的特許權使用費。
Also Read: Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs
另請閱讀：Viking Therapeutics獲得分析師對NASH和代謝項目的支持
Hansoh Pharma may co-promote or solely commercialize HS-10535 in China. Merck will record a pre-tax charge of $112 million, or $0.04 per share, to be included in GAAP and non-GAAP results in the fourth quarter of 2024.
翰森製藥可以在中國共同推廣或單獨商業化HS-10535。默沙東將在2024年第四季度記錄11200萬美金的稅前費用，此費用將包含在GAAP和非GAAP結果中，每股費用爲0.04美金。
William Blair writes that Merck is seen as a strong candidate to acquire Viking Therapeutics Inc (NASDAQ:VKTX), leading to an expected sell-off in Viking shares. However, the analyst notes that the licensing agreement with Hansoh will not hinder Merck from pursuing additional external business development opportunities in the obesity space.
威廉·布萊爾表示，默沙東被視爲收購Viking Therapeutics Inc（納斯達克：VKTX）的強有力候選者，這導致預計Viking股票會被出售。然而，分析師指出，與翰森的許可協議不會阻止默沙東追求在肥胖領域的其他外部業務發展機會。
The licensing deal highlights Merck's commitment to obesity, potentially driving further growth through additional partnerships. While the focus on Viking increases investment volatility, data from competitors or new licensing deals could significantly affect its stock.
這項許可交易突顯了默沙東對肥胖問題的承諾，可能通過額外的合作推進進一步的增長。雖然對Viking的關注增加了投資波動性，但競爭對手的數據或新的許可交易可能會顯著影響其股票。
William Blair remains confident that Viking offers a valuable asset with VK2735, a GLP-1/GIP dual agonist that could become a major player in obesity treatment due to its potential for monthly maintenance dosing and oral formulation options.
威廉·布萊爾對Viking以VK2735這一GLP-1/GIP雙激動劑作爲有價值資產的觀點保持信心，認爲其由於每月維持劑量和口服制劑選項的潛力，可能成爲肥胖治療的重要參與者。
This asset could strengthen an acquiring company's obesity portfolio, with additional potential from Viking's amylin program.
這一資產可能增強收購公司的肥胖投資組合，併爲Viking的澱粉酶項目提供額外潛力。
Overall, the analyst is optimistic about Viking's prospects, maintaining the stock as a top pick for 2025 and an Outperform rating on its shares.
總體來看，分析師對Viking的前景持樂觀態度，保持該股票爲2025年的首選，並對其股票給予超越大盤的評級。
Price Action: VKTX stock is down 11.4% at $41.37 at last check Wednesday.
價格走勢：VKTX股票週三最後檢查時下跌了11.4%，報41.37美元。
- Renewable Energy Company Ørsted Sells 50% Stake In US Solar And Battery Projects For $572 Million: Details
- 可再生能源公司Ørsted以57200萬美元出售其在美國的太陽能和電池項目50%的股份：詳情
Photo via Shutterstock.
圖片來自shutterstock。
譯文內容由第三人軟體翻譯。
